Figure 1.

Dose-response of on-treatment alanine aminotransferase (ALT) levels and hepatocellular carcinoma (HCC). There was a dose response in terms of ALT level at 12 months and risk of HCC. Kaplan-Meier analysis estimated the cumulative incidence (95% confidence interval) of composite endpoint at 6 years in of different ALT levels at 12 months: <ULN–3.51 (3.06–4.02); 1–2xULN–5.43 (4.84–6.09); and ≥2xULN–7.08 (5.65–8.85; P<0.001 for trend). Adopted from Wong et al. [23]. ULN, upper limit of normal.